Castration-resistant prostate cancer at high risk of metastasis: Enzalutamide has added benefit
In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care (IQWiG) already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison ...
Aug 19, 2020
0
3